Navigation Links
Early HIV treatment fails to restore memory T cells

Most of the body’s memory T cells vanish within weeks after a person is infected with the HIV virus. In a study from the Aaron Diamond AIDS Research Center and the Bernard-Nocht Institute appearing in the international open-access journal PLoS Medicine, researchers report that these memory T cells, mostly found in the digestive tract, tend not to return to normal even after years of treatment for HIV.

In recent years, HIV infection has been shown to deplete the body’s memory T cells quite rapidly. In particular, the memory cells in the intestinal lining are decimated within days, while the T cells usually measured in the blood fall much more gradually, typically over several years. Although T cells in the blood can return and remain at normal levels when HIV infection is treated with antiviral drugs, it has been unclear whether the intestinal mucosal memory cells return as well. By performing intestinal biopsies on volunteers who started HIV treatment shortly after infection, the researchers found that, unlike in blood, intestinal T cells remained low even after several years of HIV treatment in 70% of volunteers, even though only a tiny fraction of these cells were found to be expressing HIV. Furthermore, they found that the level of immune activation in the gastrointestinal tract remained elevated despite treatment.

The finding that intestinal immune cells do not return to normal in most people with HIV despite years of treatment raises the concern that clinical problems will result over time. Fortunately, this does not appear to be the case in most people currently being treated for HIV, some for as long as 10 years, but the results of this study suggest that vigilance is warranted for infections or other gastrointestinal problems resulting from prolonged impairment of immunity.

These results also suggest that treatments to preserve immune function early after infection should be studied, and in particular that an HIV vaccine may need to stimulate immune responses that can act very quickly following infection, before the bulk of lymphocytes capable of countering the infection are lost.
'"/>

Source:Public Library of Science


Related biology news :

1. Researchers Identify Cause of Early Bird Sleep Disorder
2. Early-stage immune system control of HIV may depend on inherited factors
3. Early-stage sperm cells created from human bone marrow
4. Early exposure to indoor fungus molecules may protect infants against future allergies
5. Protein discovery could unlock the secret to better TB treatment
6. Topical treatment shown to inhibit HIV and herpes simplex virus infection
7. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
8. Researchers add new tool to tumor-treatment arsenal
9. Potential treatments for neurofibromatosis
10. Nanoparticles offer new hope for detection and treatment
11. Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
Breaking Biology Technology: